Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities

Abstract To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved clinical diagnostic test, Tempus xT CDx. Validation was conducted via: (1) analytical evaluation of 17 arc...

Full description

Bibliographic Details

Published in:	npj Precision Oncology
Main Authors:	Ariane Lozac’hmeur, Tyler Danek, Qidi Yang, Mario G. Rosasco, John S. Welch, William Y. Go, Eric W. Ng, Armen Mardiros, David G. Maloney, Edward B. Garon, Kedar Kirtane, Diane M. Simeone, Julian R. Molina, Ameen A. Salahudeen, Michelle M. Stein, J. Randolph Hecht
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-08-01
Online Access:	https://doi.org/10.1038/s41698-024-00665-z